Gilead Sciences, Inc. vs Kimberly Clark Corp — how do they compare? Gilead Sciences, Inc. trades at $135 (market cap $164.99B), while Kimberly Clark Corp trades at $108.57 (market cap $36.48B). The key difference: Gilead Sciences, Inc. is far larger — about 4.5× Kimberly Clark Corp's market cap, and Kimberly Clark Corp pays the higher dividend (4.67%). Which is the better fit depends on your goals.
| GILD | KMB | |
|---|---|---|
Market Cap | $164.99B | $36.48B |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $134.81 |
52-Week Low | $110.56 | $93.05 |
Enterprise Value | $188.06B | $42.04B |
Dividend Yield | 2.47% | 4.67% |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →